CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
出版年份 2017 全文链接
标题
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
作者
关键词
CDK4/6 inhibitor, ESCC, Cell cycle arrest, pRb
出版物
Journal of Translational Medicine
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-06-02
DOI
10.1186/s12967-017-1231-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Targeting the RB-E2F pathway in breast cancer
- (2016) J Johnson et al. ONCOGENE
- Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer
- (2015) Natalia J. Sumi et al. ACS Chemical Biology
- Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
- (2015) Yan Zhu et al. BMC CANCER
- Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
- (2015) T. VanArsdale et al. CLINICAL CANCER RESEARCH
- CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
- (2015) M. E. Olanich et al. CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
- (2015) S K A Divakar et al. LEUKEMIA
- Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
- (2015) Agnieszka K. Witkiewicz et al. Oncotarget
- Aging interventions get human
- (2015) Brian K. Kennedy et al. Oncotarget
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
- (2014) Y.-X. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Genomic and molecular characterization of esophageal squamous cell carcinoma
- (2014) De-Chen Lin et al. NATURE GENETICS
- Esophageal Carcinoma
- (2014) Anil K. Rustgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
- (2013) Xiang-Hua Zhang et al. CANCER BIOLOGY & THERAPY
- CDK4 inhibition restores G₁-S arrest inMYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage
- (2013) Sina Gogolin et al. CELL CYCLE
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Structural Properties of Polyphenols Causing Cell Cycle Arrest at G1 Phase in HCT116 Human Colorectal Cancer Cell Lines
- (2013) Soon Shin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
- (2012) A. Kathleen McClendon et al. CELL CYCLE
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
- (2012) Patrick J. Roberts et al. JNCI-Journal of the National Cancer Institute
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started